Ovarian Cancer LateStage Therapy with PARP Inhibitor Shows Benefit

Ovarian Cancer: Late-Stage Therapy with PARP Inhibitor Shows Benefit

Niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor that hobbles tumors' ability to fix cellular DNA breaks, may have wider use in ovarian cancer than...

Original Article: Ovarian Cancer: Late-Stage Therapy with PARP Inhibitor Shows Benefit

More From BioPortfolio on "Ovarian Cancer: Late-Stage Therapy with PARP Inhibitor Shows Benefit"